Bio-Reference Laboratories, Inc. Will Offer Non-Invasive Prenatal Testing
(NIPT) From Natera
ELMWOOD PARK, N.J., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Bio-Reference
Laboratories, Inc. (Nasdaq:BRLI) announced today that the Company and Natera
have entered into a definitive agreement to commercialize the Panorama™
non-invasive prenatal screening test developed by Natera. The Panorama test
will be sold by the GenPath business unit of Bioreference.
Panorama is a simple blood test that uses cutting-edge genotyping and
sequencing technologies to identify chromosomal aneuploidies such as trisomies
13, 18, 21, and certain sex-chromosome abnormalities. According to the
proceedings of the recent Society of Maternal Fetal Medicine conference held
in San Francisco, non-invasive prenatal tests (NIPT) can reduce fetal loss by
up to 91% while detecting the same amount of aneuploidies 13, 18, 21 by
avoiding invasive Amniocentesis and chorionic villi sampling procedures.
Panorama can be used starting 9th week of pregnancy.
Marc D. Grodman, MD, CEO of BRLI, commented: "With the recent guidelines
published on non-invasive prenatal screening by ACOG, it is clear that this is
a beneficial service to women and their clinicians while facing high-risk
pregnancies. We are pleased to be able to offer Panorama as part of our
full-service prenatal offering."
Added Matthew Rabinowitz, Ph.D., chief executive officer of Natera, "Our
sophisticated technology has demonstrated that Panorama is clearly best in
class, with a sensitivity and specificity unparalleled by others, and by
combining forces with GenPath we are able to provide access to the test to the
broadest patient population possible. In addition, the test is offered with a
generous patient assistance program that enables Panorama to be available to
all pregnant women, regardless of income level."
In clinical validation studies, Panorama demonstrated a sensitivity of greater
than 99% when detecting common chromosomal abnormalities such as trisomy 21,
trisomy 18 and trisomy 13; and 92% when detecting monosomy X. In addition,
Panorama demonstrated a specificity of 100% with no false positives for all
the syndromes tested. The test uses fetal cell-free DNA found in maternal
blood and works as early as nine weeks gestation. Panorama's clinical
validation data was presented live at the annual Society of Maternal Fetal
Medicine Meeting on Feb. 15, 2013.
Panorama's technology analyzes, in a single reaction, 19,500 single nucleotide
polymorphisms (SNPs), which are the most informative portions of an
individual's DNA. It utilizes the NATUS [Next-generation Aneuploidy Testing
Using SNPs] algorithm, an advanced version of Natera's proprietary
informatics. Panorama has been validated globally and is currently being
evaluated in several other clinical trials for the detection of
geneticdisorders, including trisomy 21, trisomy 18, trisomy 13, monosomy X,
XXY, XYY, XXX and triploidy. The test uses a simple blood draw from the mother
and can be performed within the first trimester of pregnancy, as early as 9
weeks, without any risk to the fetus.
Natera is a genetic testing company that has developed a proprietary
bioinformatics-based technology (NATUS) to deliver accurate and comprehensive
high-throughput testing for reproductive indications from tiny quantities of
DNA. Natera operates a CLIA-certified laboratory in San Carlos, Calif.,
providing a host of preconception and prenatal genetic testing services. Test
offerings include pre-implantation genetic diagnosis to identify chromosomal
anomalies or inherited genetic conditions in embryos generated during an IVF
cycle; products-of-conception testing following miscarriage to rapidly and
extensively analyze fetal chromosomes in order to understand the cause of the
pregnancy loss; non-invasive prenatal testing to determine paternity; carrier
screening tests to detect whether parents carry genetic variations that may
result in disease in the child; and Panorama, a safe, simple test for pregnant
women that identifies the most common chromosomal anomalies in a fetus as
early as 9 weeks. Natera's PreNATUS clinical trial for non-invasive screening
of fetal chromosomal anomalies is funded by the NIH and is being conducted by
the leaders in maternal-fetal medicine in the United States. For more
information, visit www.natera.com.
About Bio-Reference Laboratories, Inc.
BRLI is a clinical testing laboratory offering testing, information and
related services to physician offices, clinics, hospitals, employers and
governmental units. We believe that we are the fourth largest full-service
laboratory in the United States and the largest independent regional
laboratory in the Northeastern market. BRLI offers a comprehensive list of
laboratory testing services utilized by healthcare providers in the detection,
diagnosis, evaluation, monitoring and treatment of diseases. BRLI primarily
focuses on esoteric testing, molecular diagnostics, anatomical pathology,
women's health and correctional health care.
CONTACT: Tara Mackay, Investor Relations
(201) 791-1941 (fax)
Press spacebar to pause and continue. Press esc to stop.